Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Medtronic
Federal Trade Commission
Cipla
Julphar
Johnson and Johnson

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,284,280

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,284,280 protect, and when does it expire?

Patent 9,284,280 protects UPTRAVI and is included in one NDA.

This patent has forty-three patent family members in thirty countries.

Summary for Patent: 9,284,280
Title:Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide
Abstract: A method is provided in which Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide is administered as an active ingredient to a subject for the purpose of treating or preventing certain diseases, disorders, and symptoms, or for promoting angiogenesis or gene therapy. The Form-I crystal exhibits diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2.theta. when the spectrum is obtained by using Cu K.alpha. radiation: 9.4 degrees, 9.8 degrees, 17.2 degrees, and 19.4 degrees. The targeted diseases and disorders include transient ischemic attack, diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, connective tissue disease, reocclusion/restenosis after percutaneous transluminal coronary angioplasty, arteriosclerosis, thrombosis, hypertension, pulmonary hypertension, ischemic disorder, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, allergy, bronchial asthma, ulcer, pressure ulcer (bedsore), restenosis after coronary intervention, thrombocytopenia by dialysis, the diseases in which fibrosis of organs or tissues is involved, erectile dysfunction, inflammatory bowel disease, and gastritis.
Inventor(s): Itou; Hideyuki (Kyoto, JP)
Assignee: NIPPON SHINYAKU CO., LTD. (Kyoto, JP)
Application Number:14/160,641
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,284,280

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-006 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,284,280

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-151727Jun 26, 2009
Japan2009-151728Jun 26, 2009
Japan2009-151729Jun 26, 2009

International Family Members for US Patent 9,284,280

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077242 ➤ Sign Up
Australia 2010263569 ➤ Sign Up
Brazil PI1015936 ➤ Sign Up
Canada 2764475 ➤ Sign Up
China 102459198 ➤ Sign Up
China 104326991 ➤ Sign Up
Colombia 6430432 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Chubb
Fish and Richardson
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.